Nello Mainolfi, Chief Executive Officer at Kymera Therapeutics, Inc. (KYMR), sold 60,000 shares at $78.52 ($4.7M) on 2025-12-31, disclosed to the SEC on 2025-12-31.
Scheduled sale ($4.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $77.95 | 23,986 | $1.9M | 39.9% |
| 2 | $77.95 | 23,986 | $1.9M | 39.9% |
| 3 | $78.52 | 6,014 | $472K | 10.1% |
| 4 | $78.52 | 6,014 | $472K | 10.1% |
| Total | $78.06 avg | 60,000 | $4.7M | 100% |
| Filing → |
| KYMR | SELL | 2026-07-02 | $9.2M | — | Filing → |
| KYMR | SELL | 2026-04-29 | $2.4M | — | Filing → |
| KYMR | SELL | 2026-02-25 | $2.7M | — | Filing → |